MMP9 and breast carcinoma: Treatment with sHA, however, lead to the downregulation of MT1-MMP, known to be involved in breast cancer cell migration and invasion, as well as the downregulation of MMP2 and MMP9, two MMPs with pivotal role in ECM degradation [23].